Imagion Biosystems Limited
IBXXF
$0.015
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -98.48% | -98.49% | -75.94% | -75.38% | 133.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -98.48% | -98.49% | -75.94% | -75.38% | 133.71% |
| Cost of Revenue | 78.58% | 75.32% | -97.76% | -97.71% | -85.13% |
| Gross Profit | -143.74% | -142.92% | -22.35% | -20.52% | 184.62% |
| SG&A Expenses | -70.35% | -70.90% | -84.91% | -84.55% | -64.56% |
| Depreciation & Amortization | -98.89% | -98.89% | -98.72% | -98.67% | -35.14% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -55.25% | -56.09% | -90.29% | -90.06% | -68.13% |
| Operating Income | -21.35% | -19.05% | 103.87% | 103.96% | 87.40% |
| Income Before Tax | -5.78% | -3.80% | 88.73% | 88.46% | 80.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.78% | -3.80% | 88.73% | 88.46% | 80.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.78% | -3.80% | 88.73% | 88.46% | 80.39% |
| EBIT | -21.35% | -19.05% | 103.87% | 103.96% | 87.40% |
| EBITDA | -107.10% | -103.28% | 105.07% | 108.33% | 92.00% |
| EPS Basic | 83.12% | 83.12% | 93.50% | 93.32% | 83.04% |
| Normalized Basic EPS | 82.29% | 83.33% | 93.62% | 93.33% | 83.10% |
| EPS Diluted | 82.47% | 83.12% | 93.50% | 93.32% | 83.04% |
| Normalized Diluted EPS | 82.29% | 83.33% | 93.62% | 93.33% | 83.10% |
| Average Basic Shares Outstanding | 516.73% | 516.73% | 75.03% | 75.03% | 15.58% |
| Average Diluted Shares Outstanding | 516.73% | 516.73% | 75.03% | 75.03% | 15.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |